MOLN — Molecular Partners AG Income Statement
0.000.00%
Last trade - 00:00
- $162.10m
- -$20.02m
- CH₣7.04m
- 35
- 20
- 54
- 29
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 20.4 | 9.34 | 9.75 | 190 | 7.04 |
Cost of Revenue | |||||
Gross Profit | 20.3 | 8.78 | 9.69 | 189 | 7.03 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 57 | 67.7 | 73.2 | 73 | 68.1 |
Operating Profit | -36.7 | -58.3 | -63.4 | 117 | -61.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -36.3 | -62.8 | -63.8 | 118 | -62 |
Provision for Income Taxes | |||||
Net Income After Taxes | -36.3 | -62.8 | -63.8 | 118 | -62 |
Net Income Before Extraordinary Items | |||||
Net Income | -36.3 | -62.8 | -63.8 | 118 | -62 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -36.3 | -62.8 | -63.8 | 118 | -62 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.69 | -2.51 | -2.06 | 3.63 | -1.89 |
Dividends per Share |